Long-term cultivation of retinal pigment epithelium cells on nanofiber scaffolds
Graefe's Archive for Clinical and Experimental Ophthalmology · 2025
DOI: 10.1007/s00417-024-06707-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2025. Verfasst von Julian A Zimmermann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital Munster, Munster, Germany. Hauptthemen laut MEDLINE: Retinal Pigment Epithelium, Nanofibers, Tissue Scaffolds, Cell Culture Techniques. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität Münster.
Abstract (Originalsprache)
Purpose
The retinal pigment epithelium (RPE) plays an important role in the pathogenesis of age-related macular degeneration (AMD) and other retinal degenerative diseases. The introduction of healthy RPE cell cultures into the subretinal space offers a potential treatment strategy. The aim of this study was the long-term culture and characterisation of RPE cells on nanofiber scaffolds.
Methods
Nanofiber scaffolds consisting of polycaprolactone (PCL) and collagen were prepared by electrospinning. Porcine RPE cell cultures were maintained on PCL scaffolds, PCL-collagen scaffolds, and controls at the bottom of 24-well plates. Cell culture analysis was performed by immunohistochemistry, while the release of inflammatory cytokines IL-6, IL-8, TNF-α, and PDGF-β was measured by ELISA and multiplex assays. Ultrastructural features were examined by transmission electron microscopy.
Results
The observation period averaged 42.7 weeks for controls, 38.7 weeks for PCL scaffold cultures, and 36.1 weeks for PCL-collagen scaffold cultures, with cell number and morphology remaining stable. TNF-α levels in the supernatants were minimal, IL-6 levels were consistently low, and IL-8 levels decreased from initially high to lower levels over time.
Conclusion
RPE cells were stably cultured on nanofiber scaffolds for extended periods of time. The long-term physiological properties of RPE cells, including phagocytic ability and visual cycle enzyme activity, need to be further investigated before clinical application. In addition, controlling the expression of inflammatory mediators is a major challenge. Despite these hurdles, overcoming them is critical given the increasing prevalence of retinal degenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University Hospital Munster, Munster, Germany.
- Institute of Musculoskeletal Medicine, University Hospital Munster, Munster, Germany.
- Institute of Polymer Materials, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
- Department of Ophthalmology, University Medical Center Rostock, Rostock, Germany.
- Department of Ophthalmology, University Hospital Munster, Munster, Germany. peter.heiduschka@ukmuenster.de.
Förderung
- Universität Münster
Zitieren
APA
Zimmermann, J. A., Irlenbusch, L., Hansen, U., Himmler, M., Zeng, C., Eter, N., Fuchsluger, T., & Heiduschka, P. (2025). Long-term cultivation of retinal pigment epithelium cells on nanofiber scaffolds. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06707-3
Vancouver
Zimmermann JA, Irlenbusch L, Hansen U, Himmler M, Zeng C, Eter N, et al. Long-term cultivation of retinal pigment epithelium cells on nanofiber scaffolds. Graefe's Archive for Clinical and Experimental Ophthalmology. 2025. doi:10.1007/s00417-024-06707-3
BibTeX
@article{Zimmermann2025,
author = {Zimmermann, Julian A and Irlenbusch, Lucy and Hansen, Uwe and Himmler, Marcus and Zeng, Chun and Eter, Nicole and Fuchsluger, Thomas and Heiduschka, Peter},
title = {Long-term cultivation of retinal pigment epithelium cells on nanofiber scaffolds},
journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
year = {2025},
doi = {10.1007/s00417-024-06707-3}
}
EUVIMED